Search

Your search keyword '"Fleischmann, R."' showing total 1,390 results

Search Constraints

Start Over You searched for: Author "Fleischmann, R." Remove constraint Author: "Fleischmann, R."
1,390 results on '"Fleischmann, R."'

Search Results

2. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

3. Dynamical phase diagram of Gaussian BEC wave packets in optical lattices

4. Experimental Observation of a Fundamental Length Scale of Waves in Random Media

5. How branching can change the conductance of ballistic semiconductor devices

6. Avalanches of Bose-Einstein Condensates in Leaking Optical Lattices

7. Fractal Conductance Fluctuations of Classical Origin

8. Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis

9. Mesoscopic Rectifiers Based on Ballistic Transport: Playing off Classical against Quantum Mechanics

10. Quantum Coherence Beyond the Thermal Length

11. Coherent Branched Flow in a Two-Dimensional Electron Gas

12. Skipping orbits and enhanced resistivity in large-diameter InAs/GaSb antidot lattices

13. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis

14. Nonlinear Dynamics of Composite Fermions in Nanostructures

15. Quenched and Negative Hall Effect in Periodic Media: Application to Antidot Superlattices

16. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE

21. The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept

26. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

28. POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS

30. POS0239 RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3b/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS

34. POS0579 ABSENCE OF ASSOCIATION BETWEEN ABATACEPT EXPOSURE LEVELS AND INITIAL INFECTION IN PATIENTS WITH RA: A POST HOC ANALYSIS OF THE RANDOMIZED, PLACEBO-CONTROLLED AVERT-2 STUDY

41. Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: results from two phase 3 studies (RA-BEAM and RA-BEGIN)

47. Cost-Effective Learning for Classifying Human Values

Catalog

Books, media, physical & digital resources